Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

BERKELEY HEIGHTS, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) today announced financial results for the quarter ended June 30, 2008. The Company recorded significant milestones in the second quarter, including the following:

-- NDA amendment for Genasense(R) in CLL submitted to FDA

-- AGENDA Phase 3 trial of Genasense in melanoma updated at EADO

-- Clinical hold on tesetaxel, a leading, clinical-stage oral taxane, lifted by FDA
-- Pharmacokinetics of oral G4544 for bone disease presented at ASCO

-- Company closes $20 million financing in convertible notes

"Genta has three high-value clinical-stage products, and we have now secured funding that should enable us to conclude both our NDA amendment for Genasense(R) in CLL, as well as enrollment into our Phase 3 program in melanoma," said Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "FDA has targeted December 3, 2008 as the action date for the CLL NDA amendment, and we expect to report AGENDA results in melanoma during 2009. In response to Genta's regulatory submission, FDA has now lifted the clinical hold on tesetaxel, which will allow us to resume clinical trials with a leading oral taxane that addresses a large, well-characterized market. Our portfolio includes unique compounds that offer significant revenue and partnering opportunities."

Highlights of the Genta programs appear below.

Genasense: The Leading Antisense Drug in Clinical Development

Genasense in Melanoma: Genta is currently enrolling patients with advanced melanoma in a Phase 3 trial of Genasense plus chemotherapy, known as AGENDA. AGENDA is a randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... has traditionally been a face-to-face interaction in which people ... ,Since the technology boom, the networking landscape has changed ... list servs and online social networking. People no longer ... relationships. , ,The Midwest has been generously affected ...
... bacteria that causes tuberculosis (TB) and leprosy are notoriously ... held in check for the past 50 years by ... therapy. , ,Now, however, a new chink has been ... diseases difficult to treat. The discovery, reported today (May ...
... committed to helping improve patient safety and healthcare through ... administration and the efforts of Secretary Thompson and his ... If you are interested in learning more about this ... ,The University of Wisconsin and UW Health in ...
Cached Biology Technology:Using Technology to Professionally Network in the Midwest 2Using Technology to Professionally Network in the Midwest 3Using Technology to Professionally Network in the Midwest 4UW discovery could lead to new TB treatments 2UW discovery could lead to new TB treatments 3The doctor is in: Thompson prescribes better health information technology 2The doctor is in: Thompson prescribes better health information technology 3The doctor is in: Thompson prescribes better health information technology 4
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
(Date:4/17/2014)... Press journal Current Biology on April 17 ... lives. The Brazilian insects, which represent four distinct but ... the first example of an animal with sex-reversed genitalia. ... several different animals, Neotrogla is the only ... says Kazunori Yoshizawa from Hokkaido University in Japan. , ...
(Date:4/17/2014)... chock full of wild animals and plant life, but ... are churning away in the soil, decomposing organic matter ... vital role these fungi play in ecological systems, their ... of scientists has generated a genetic map of more ... work was published this week in the Proceedings ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3In sex-reversed cave insects, females have the penises 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... Jan. 28, 2009 Mice with increased levels of a ... diet, researchers at UT Southwestern Medical Center have found. ... to the "weight-loss hormone," leptin, the researchers report. ... useful as a therapy against obesity, said Dr. Masashi Yanagisawa, ...
... and engineers will face a host of obstacles over ... of people caught up in a water shortage crisis, ... a briefing at the Broadcast Center of the National ... Chemical Society,s Global Challenges/Chemistry Solutions. The American ...
... Dog owners who sleep with their pet or permit licks on ... half of owners bond with their pets in these ways. ... these dog owners are no more likely to share the same ... are other dog owners. Dr. Kate Stenske, a clinical assistant ...
Cached Biology News:Natural brain substance blocks weight gain in mice, UT Southwestern researchers discover 2Substantial work ahead for water issues, say scientists at ACS' Final Report briefing 2Substantial work ahead for water issues, say scientists at ACS' Final Report briefing 3Dog owners more likely to share germs with pets by not washing hands than by sleeping with dog 2
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Request Info...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: